Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Heterocyclic Compounds
Heterocyclic Compounds, Fused-Ring
Clear Filters

Search Clinical Trials

64 Results
Completed
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
The primary objective is to investigate whether all doses (0.1 mg/kg, 0.2 mg/kg, 0.5 mg/kg, and 1.0 mg/kg) of ketamine are superior to active placebo (midazolam 0.045 mg/kg) therapy in …
Baylor Role: Collaborator
Terminated
Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer
For patients with stage IIIB/IV non-small cell lung cancer, who did not progress after first line chemotherapy, lenalidomide 10mg/day orally will be administered as maintenance therapy until disease progression or …
Baylor Role: Collaborator
Completed
Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse
The noradrenergic system, especially the alpha 1-adrenergic receptor, may play an important role in cocaine addiction in humans. Doxazosin is a long-acting and selective alpha 1-adrenergic receptor blocker, which inhibits …
Baylor Role: Collaborator
Active, Not Recruiting
iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
Patients give blood to make GD2-T cells that are grown and frozen. To get the GD2-CAR to attach to the surface of the T-cell, a gene is inserted into the …
Baylor Role: Lead Sponsor
Recruiting
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Patients will give the investigators blood to make CD19 CD28 (with and without CD137) chimeric receptor-T cells in the laboratory. These cells will be grown and frozen. To make the …
Baylor Role: Lead Sponsor
Completed
Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate
The study participant will receive the drug methotrexate as a patient in the hospital. High dose methotrexate will be given as a 24-hour infusion as part of the care determined …
Baylor Role: Lead Sponsor
Terminated
Pentoxifylline Therapy in Biliary Atresia
Biliary atresia (BA) is a devastating liver disease of infancy of unknown etiology, characterized by bile duct obstruction, live fibrosis, and cirrhosis. BA has no known medical treatments. The only …
Baylor Role: Lead Sponsor
Terminated
Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide
Previously, some of the cancer cells were taken from the subject's body and separated in the laboratory and a specially produced human virus (adenovirus) that carries the IL-2 gene was …
Baylor Role: Lead Sponsor
Completed
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies
The subject will need to have a variety of tests, exams, or procedures to find out if s/he can be on the study. The subject will also require placement of …
Baylor Role: Lead Sponsor
Completed
Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A
At first the subject will have 2 cycles of cancer drugs (Doxorubicin, Bleomycin, Vincristine, Etoposide, Prednisone, Cyclophosphamide). The doctors call this combination of cancer drugs ABVE-PC for short. A cycle …
Baylor Role: Lead Sponsor